Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
45 results about "Head neck cancer" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Anti-il-6 antibodies for the treatment of anemia
ActiveUS20120128626A1Inhibition effectInhibitionBiocidePeptide/protein ingredientsCvd riskHead and neck cancer
The present invention is directed to therapeutic methods using IL-6 antagonists such as anti-IL-6 antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat anemia (e.g., anemia associated with chemotherapy) including persons on a treatment regimen with a drug or chemotherapy and / or radiation for cancer (e.g., head and neck cancer) that is associated with increased risk of anemia.
Owner:ALDERBIO HLDG LLC +1
Diagnostic tests for predicting prognosis, recurrence, resistance or sensitivity to therapy and metastatic status in cancer
InactiveUS20140342946A1Low costReduce morbidityMicrobiological testing/measurementProtein nucleotide librariesParanasal Sinus CarcinomaDiagnostic test
The present invention describes a method utilizing a set of genes or gene products whose altered expression in cancer tissue, particularly head and neck cancer and other carcinomas, or its adjacent normal tissues predicts (a) probability of recurrence in time after treatment (b) sensitivity or resistance to therapies or (c) probability of metastasis at the time of initial discovery of the tumor. Furthermore, the invention describes methods of determining the molecular signature in tumor tissues, tissues adjacent to the tumor, or in saliva by using DNA microarray techniques, quantitative real-time PCR, immunohistochemistry or other methods that are used for determining gene or gene product expression levels.
Owner:KURIAKOSE MONI ABRAHAM +1
Antibody fragment-targeted immunoliposomes for systemic gene delivery
InactiveUS7479276B1Improve the level ofEfficient transfectionVectorsAntibody ingredientsGene deliveryAntiendomysial antibodies
Nucleic acid-immunoliposome compositions useful as therapeutic agents are disclosed. These compositions preferably comprise (i) cationic liposomes, (ii) a single chain antibody fragment which binds to a transferrin receptor, and (iii) a nucleic acid encoding a wild type p53. These compositions target cells which express transferrin receptors, e.g., cancer cells. These compositions can be used therapeutically to treat persons or animals who have cancer, e.g., head and neck cancer, breast cancer or prostate cancer.
Owner:SYNERGENE THERAPEUTICS +1
Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
InactiveUS20150132253A1Effectively preventingEffectively treatingHeavy metal active ingredientsOrganic active ingredientsDiseaseCombined Modality Therapy
The present invention provides a combination therapy for effectively treating and / or preventing diseases associated with cells expressing CLDN18.2, including cancer diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder and metastases thereof.
Owner:ASTELLAS PHARMA INC +1
Phosphaplatins and their use for treatment of cancers
Stable monomeric phosphaplatins, namely, (pyrophosphato)platinum(II) or platinum(IV) complexes containing a cis-cyclohexanediamine ligand or enantiomerically enriched or enantiopure trans-cyclohexanediamine ligands, and synthesis of these complexes, are provided. Efficacies and toxicities of the phosphaplatin compounds are determined toward a variety of cancers, including sensitive and resistant ovarian cancers, head and neck, and colon cancers. Compositions comprising the platinum complexes, and methods for treatment of proliferative diseases or disorders by means of the complexes or the compositions comprising them are disclosed.
Owner:OHIO UNIV
Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
ActiveUS20150157711A1High expressionStabilizing and increasing expressionHeavy metal active ingredientsPeptide/protein ingredientsDiseaseCombined Modality Therapy
The present invention provides a combination therapy for effectively treating and / or preventing diseases associated with cells expressing CLDN18.2, including cancer diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder and metastases thereof.
Owner:TRON TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG UNIVERS +1
Monoclonal antibodies against claudin-18 for treatment of cancer
The present invention provides antibodies useful as therapeutics for treating and / or preventing diseases associated with cells expressing CLD18, including tumor-related diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder.
Owner:ASTELLAS PHARMA INC +1
Monoclonal antibodies against claudin-18 for treatment of cancer
The present invention provides antibodies useful as therapeutics for treating and / or preventing diseases associated with cells expressing CLD18, including tumor-related diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder.
Owner:ASTELLAS PHARMA INC +1
Biomarkers for human papilloma virus-associated cancer
ActiveUS20090136486A1Microbiological testing/measurementAntibody ingredientsSynaptonemal complex protein 2Antigen
Cervical cancer cells and HPV+ head and neck cancer cells express three testis-specific genes not normally expressed in somatic cells: testicular cell adhesion molecule 1 (TCAM1), synaptonemal complex protein 2 (SYCP2) and stromal antigen 3 (STAG3). Among the three markers, TCAM1 and SYCP2 are early detection markers. Various methods for identifying a human or non-human animal as a candidate for further examination for cervical cancer, preneoplastic lesion for cervical cancer, head and neck cancer, or preneoplastic lesion for head and neck cancer are disclosed. Methods of detecting said cancers and preneoplastic lesions, methods of screening for drugs for treating said cancers and preneoplastic lesions, methods for monitoring the effectiveness of a treatment for said cancers, and methods of treating said cancers are also disclosed. Further disclosed are kits that can be used to practice the above methods.
Owner:WISCONSIN ALUMNI RES FOUND
Phosphaplatins and their use for treatment of cancers
Stable monomeric phosphaplatins, namely, (pyrophosphato)platinum(II) or platinum(IV) complexes containing a cis-cyclohexanediamine ligand or enantiomerically enriched or enantiopure trans-cyclohexanediamine ligands, and synthesis of these complexes, are provided. Efficacies and toxicities of the phosphaplatin compounds are determined toward a variety of cancers, including sensitive and resistant ovarian cancers, head and neck, and colon cancers. Compositions comprising the platinum complexes, and methods for treatment of proliferative diseases or disorders by means of the complexes or the compositions comprising them are disclosed.
Owner:OHIO UNIV
Radiolabeled 1-acetate pet imaging for radiotherapy in head and neck cancer
InactiveUS20100258138A1Good curative effectOrganic chemistrySurgerySalivary gland functionPet imaging
The present invention provides methods of using optimal PET tracers for diagnosing head and neck cancer. Methods for in vivo imaging uses of the PET tracers that are suitable for uses in radiation therapy (RT) in head and neck cancer and evaluation of salivary gland function are also provided. A pharmaceutical comprising the PET tracer and a kit for the preparation of the pharmaceutical are provided as well.
Owner:GE HEALTHCARE LTD
Compositions and Methods for Increasing Proliferation of Adult Salivary Stem Cells
ActiveUS20140323520A1Increased proliferationIncrease the number ofBiocideOrganic chemistryAgonistBiology
The present disclosure provides methods of increasing proliferation of adult salivary stem cells. The methods include contacting adult salivary stem cells in vivo, in vitro, or ex vivo with an aldehyde dehydrogenase (ALDH) agonist. Increasing proliferation of adult salivary stem cells can be carried out to provide for an increase in the number of adult salivary stem cells in an indi vidual undergoing radiotherapy for head and neck cancer.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV
Novel tumor targeting contrast agent
The invention provides a novel tumor targeting contrast agent, which is characterized in that an apoferritin cage cavity housing is assembled with heavy chain by human ferritin, and a pharmaceutically acceptable magnetic resonance imaging contrast reinforcing agent is coated in the apoferritin cage cavity, the formed compound is a novel MRI tumor imaging contrast agent possessing a tumor specific targeting function. The contrast agent of the invention has the characteristics of no toxicity or low toxicity, good tumor targeting, strong specificity, less usage amount, high in vivo stability and the like, and is especially suitable for magnetic resonance imaging contrast of tumor tissue like liver cancer tumor, melanin tumor, lung cancer tumor, breast cancer tumor, colon cancer / rectal cancer tumor, pancreas cancer tumor, stomach cancer tumor, ovary cancer, head and neck cancer, neuroglioma.
Owner:杨静雯
Method on clinical applications in head neck cancer by using DSG3 molecule for predicting malignant degree of cancer, serving as a molecular target and using RNA jamming sequence on inhibition-specific of DSG3 expression
InactiveUS20090029354A1Inhibit growthPrevent invasionSugar derivativesMicrobiological testing/measurementAbnormal tissue growthCancer cell
The present invention provide a method for analyzing the DSG3 overexpression in tumor tissues with clinical features of cancer cells to validate that DSG3 overexpression is relates to size, depth and migration of tumor. Therefore, DSG3 overexpression is capable for using in clinical applications, determining malignant degree of tumor, serving as molecular target in Head Neck Cancer (HNC). Moreover, a jamming sequence, RNA, is designed to act on DSG3 mRNA and is effective inhibition-specific DSG3 expression, and then inhibits cell growth, invasion and migration in HNC.
Owner:CHANG GUNG MEMORIAL HOSPITAL +1
HNC (Head and Neck Cancer) prognosis biomarker based on lymph node microbial flora and application of HNC prognosis biomarker
PendingCN113684242AGood forecastThe value of good practical applicationHealth-index calculationMicrobiological testing/measurementFloraMicrobiome
The invention provides an HNC (Head and Neck Cancer) prognosis biomarker based on a lymph node microbial flora and application of the HNC prognosis biomarker, and belongs to the technical field of disease prognosis and molecular biology. According to the invention, the 16S ribosomal RNA gene of the lymph node microbial flora of an HNC patient is subjected to high-throughput sequencing, so that it is proved that different species exist in flora species of metastatic lymph nodes and non-metastatic lymph nodes in the HNC patient; furthermore, through a microbial flora symbiotic relationship network, it is found that the flora interrelation between the species of the metastatic lymph node and the species of the non-metastatic lymph node of the HNC patient is also different at the genus level; the result discovers the characteristics of the microbiome of the metastatic lymph node and the non-metastatic lymph node of the HNC patient for the first time; and meanwhile, it is known by analysis that the flora difference characteristics (diversity index values and relative abundance of different species) have a good prediction effect on the lifetime (total lifetime and three-year lifetime) of the HNC patient, so that the invention has a good practical application value.
Owner:SHANDONG UNIV +1
Drug conjugates comprising antibodies against claudin 18.2
ActiveUS20180117174A1Effectively treating and preventingDipeptide ingredientsImmunoglobulins against cell receptors/antigens/surface-determinantsEsophageal cancerOvarian cancer
The present invention provides anti-CLDN18.2 antibody-drug conjugates which are effective for treating and / or preventing cancer diseases associated with cells expressing CLDN18.2, including gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder and metastases thereof.
Owner:TRON TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG UNIVERS +1
Application of PPAR delta inhibitor combined immunotherapy drug in preparation of antitumor drugs
PendingCN112972688AReduce proliferationReduce functionAntibody ingredientsImmunoglobulinsProstate cancerStomach cancer
The invention relates to application of a PPAR delta inhibitor combined immunotherapy drug in preparation of antitumor drugs. The immunotherapy drug is an immune agonist or an immune checkpoint inhibitor. The tumors are preferably melanoma, breast cancer, ovarian cancer, pancreatic cancer, lung cancer, liver cancer, esophageal cancer, colorectal cancer, colon cancer, lymphoma, brain tumor, sarcoma, cervical cancer, prostate cancer, bladder cancer, osteosarcoma, head and neck cancer, renal cell cancer or gastric cancer. The medicine disclosed by the invention is remarkable in anti-tumor effect, high in targeting property and very small in side effect.
Owner:JILIN UNIV FIRST HOSPITAL
Pharmaceutical composition comprising recombinant hemoglobin protein or subunit-based therapeutic agent for cancer targeting treatment
ActiveUS9814759B2Efficient killingEffective treatmentOrganic active ingredientsPeptide/protein ingredientsLymphatic SpreadActive agent
The present invention provides a pharmaceutical composition containing recombinant hemoglobin protein or tetramer or dimer or subunit for tissue oxygenation and treating cancer. The recombinant hemoglobin protein or tetramer or dimer or subunit-based therapeutic agent is also effective for treating cancer. The recombinant hemoglobin or tetramer or dimer or its subunit moiety can target cancer cells and the therapeutic moiety (i.e. active agent / therapeutic drug) can kill the cancer cells efficiently. The recombinant hemoglobin or tetramer or dimer or its subunit-based therapeutic agent used in the present invention can be used in the treatment of various cancers such as pancreatic cancer, leukemia, head and neck cancer, colorectal cancer, lung cancer, breast cancer, liver cancer, nasopharyngeal cancer, esophageal cancer, prostate cancer, stomach cancer and brain cancer. The composition can be used alone or in combination with other therapeutic agent(s) such as chemotherapeutic agent, radiotherapeutic agent, anti-cancer protein drug to give a synergistic effect on cancer treatment, inhibiting metastasis and / or reducing recurrence.
Owner:CHEER GLOBAL
Tumor targeted molecule and application thereof
InactiveCN102372771AHigh speedMacromolecular non-active ingredientsIn-vivo testing preparationsTumor targetPancreas Cancers
The invention provides a tumor targeted molecule capable of specifically binding to a plurality of tumors, i.e., ferritin, and a contrast agent for diagnosis of tumor or a therapeutic drug containing the tumor targeted molecule. The contrast agent or the therapeutic drug has the characteristics of no or low toxicity, strong specificity, a small utilization amount, high stability in vivo, etc, and is especially applicable to targeted diagnosis or treatment of malignant tumor tissue, e.g., liver cancer tumor, melanin tumor, lung cancer tumor, breast cancer tumor, colonic / rectal cancer tumor, pancreas cancer tumor, stomach cancer tumor, ovarian cancer, head and neck cancer, neuroglioma, etc.
Owner:杨静雯
Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
ActiveUS9433675B2High affinityStrong specificityHeavy metal active ingredientsBiocideDiseaseEsophageal cancer
Owner:TRON TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITAETSMEDIZIN DER JOHANNES GUTENBERG UNIV MAINZ GEMEINNUETZIGE GMBH +1
Monoclonal antibody against claudin-18 for the treatment of cancer
The present invention provides antibodies, which can be used as a therapeutic agent for treating and / or preventing diseases associated with cells expressing CLD18, including tumor-related diseases, such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, Liver, head and neck, and gallbladder cancers.
Owner:ASTELLAS PHARMA INC +1
Pharmaceutical composition comprising modified hemoglobin-based therapeutic agent for cancer targeting treatment and diagnostic imaging
ActiveUS9636404B2Efficient killingEffective treatmentPeptide/protein ingredientsRadioactive preparation carriersLymphatic SpreadCancer targeting
The present invention provides a pharmaceutical composition containing hemoglobin-based therapeutic agent for treating cancer. The hemoglobin moiety can target cancer cells and the therapeutic moiety (i.e. active agent / therapeutic drug) can kill the cancer cells efficiently. The hemoglobin-based therapeutic agent used in the present invention can be used in the treatment of various cancers such as pancreatic cancer, leukemia, head and neck cancer, colorectal cancer, lung cancer, breast cancer, liver cancer, nasopharyngeal cancer, esophageal cancer, prostate cancer, stomach cancer and brain cancer. The composition can be used alone or in combination with other therapeutic agent(s) such as chemotherapeutic agent to give a synergistic effect on cancer treatment, inhibiting metastasis and / or reducing recurrence. The presently claimed hemoglobin-based 5FU-two-dye conjugate and / or hemoglobin-based 5FU-one-dye conjugate can also be used in live-cell imaging and diagnostic imaging.
Owner:VISION GLOBAL HLDG
Monoclonal antibody against claudin-18 for the treatment of cancer
Owner:ASTELLAS PHARMA INC +1
Carborane celecoxib, preparation thereof and application thereof in head and neck cancer boron neutron capture therapy drugs
ActiveCN112358492AStrong selective uptakeGood killing effectEnergy modified materialsGroup 3/13 element organic compoundsSide effectCancer cell
The invention discloses preparation of carborane celecoxib and application of carborane celecoxib in head and neck cancer boron neutron capture therapy drugs, and relates to the field of medicinal chemistry and radiological medicine. The compound can be prepared from celecoxib, 3-propargyl bromide and decaborane in a toluene solution through substitution and addition reactions step by step. The preparation process is simple and easy to operate, and the product is high in yield and purity. Head and neck cancer cell experiment results prove that the compound has high selectivity on head and neckcancer cells and has an obvious apoptosis induction effect on the head and neck cancer cells in boron neutron capture therapy. Compared with an existing clinical medicine applied to boron neutron capture therapy, the compound is high in boron loading capacity and high in tumor selectivity, the anti-inflammatory effect can be achieved while the radiotherapy effect is achieved, and the toxic and side effects of therapy are reduced.
Owner:LANZHOU UNIVERSITY
Compositions comprising amino acids for use in the treatment of mucositides in neoplasia patients undergoing radiation therapy and/or chemotherapy
Amino acid composition for use in the treatment of mucositis in patients suffering from head and neck cancer, undergoing radiation therapy and / or chemotherapy, the composition comprising an active agent, the active agent comprising the amino acids: glutamine, leucine, isoleucine, valine, lysine, threonine, histidine, phenylalanine, methionine, tryptophan, tyrosine, and cystine, wherein the glutamine:leucine weight ratio is in the range 4.3 to 5.3.
Owner:PROFESSIONAL DIETETICS SPA
HPV16, 18L1 recombinant DNA vaccine for preventing and treating esophagus cancers
An HPV16, 18L1 recombinant DNA vaccine for preventing and treating esophagus cancer belongs to the technical field of biological medicines. The invention provides an optimal gene sequence coding the major capsid protein L1 of HPV16, 18, a pVR-HPV16, 18L1 DNA vaccine containing the gene sequence, and a preparation method for the pVR-HPV16, 18L1 DNA vaccine. The HPV16, 18L1 recombinant DNA vaccine can also be used for preparing a vaccine for preventing and treating diseases such as cervical cancer and head and neck cancer, caused by HPV.
Owner:BEIJING UNIV OF TECH
Method for diagnosing head and neck cancer via bacterial metagenomic analysis
InactiveUS20210189464A1Slow onsetAvoid seizuresMicrobiological testing/measurementExtracellular vesicleTherapeutic effect
Provided is a method of diagnosing head and neck cancer by analyzing an increase or decrease in content of specific bacteria-derived extracellular vesicles through bacterial metagenomic analysis using normal individual- and subject-derived samples, wherein the risk of head and neck cancer can be diagnosed through metagenomic analysis of bacteria-derived extracellular vesicles using a human body-derived sample, and thus a risk group of head and neck cancer can be diagnosed early and predicted, thereby delaying the onset of head and neck cancer or preventing the onset of head and neck cancer through appropriate management, and even after head and neck cancer occur, early diagnosis for head and neck cancer can be implemented, thereby lowering the incidence of head and neck cancer and increasing therapeutic effects.
Owner:MD HEALTHCARE INC
Biomarker for monitoring and therapeutic effect evaluation of head and neck cancer
PendingCN111172284AStrong specificityAccurate judgmentMicrobiological testing/measurementTherapeutic effectOncology
The invention relates to the field of clinical diagnosis of head and neck cancer, in particular to a biomarker for monitoring and therapeutic effect evaluation of the head and neck cancer. The invention discloses application of an m5C regulatory gene in preparation of a monitoring reagent or kit for diagnosis, monitoring, therapeutic effect evaluation or metastasis and recurrence. The biomarker has high specificity in monitoring and therapeutic effect evaluation of the head and neck cancer, and can be used for dynamic monitoring of recurrence and metastasis. The gene marker can be combined with other clinical indicators, and provide more accurate judgments for screening, diagnosis, therapy and prognosis of the head and neck cancer.
Owner:THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIV
Functional genomics screening platform for head and neck cancer
ActiveUS9926605B2Improve the level ofIncreased proliferationOrganic active ingredientsMicrobiological testing/measurementAbnormal tissue growthCell survival
The present invention relates to HPV-positive as well as HPV-negative screening platforms that are highly serum-dependent, for use as HNSCC models. These HNSCC models die reproducibly in serum-deprived conditions and the introduction of driver mutations (or increased levels of the WT gene) confers enhanced cell survival and proliferation under serum deprivation. These platforms have the major advantages of allowing functional screening of mutations in relevant HNSCC models (HPV-positive and HPV-negative). In addition to oncogene screening, this model can also be used in drug discovery. Specifically, cells expressing mutations that confer increased survival can then be screened against panels of therapeutic agents to determine if the mutation(s) can predict the optimal treatment for patients whose tumors harbor the mutation(s).
Owner:UNIVERSITY OF PITTSBURGH
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com